# Imetelstat Sodium in Treating Younger Patients With Relapsed or Refractory Solid Tumors

> **NCT02011126** · PHASE2 · WITHDRAWN · sponsor: **Children's Oncology Group**

## Conditions studied

- Hepatoblastoma
- Previously Treated Childhood Rhabdomyosarcoma
- Recurrent Childhood Liver Cancer
- Recurrent Childhood Rhabdomyosarcoma
- Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
- Recurrent Neuroblastoma
- Recurrent Osteosarcoma
- Rhabdomyosarcoma

## Interventions

- **DRUG:** Imetelstat Sodium
- **OTHER:** Laboratory Biomarker Analysis

## Key facts

- **NCT ID:** NCT02011126
- **Lead sponsor:** Children's Oncology Group
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2014-06-30
- **Primary completion:** 2016-03-25
- **Final completion:** —
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** IND no longer available.
- **Last updated:** 2018-08-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02011126

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02011126, "Imetelstat Sodium in Treating Younger Patients With Relapsed or Refractory Solid Tumors". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT02011126. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*